• Explore /
  • Poster
  • / Efficacy outcomes of nivolumab + cabozantinib versus pembrolizumab + axitinib in patients with advanced renal cell carcinoma (aRCC): Matching-adjusted indirect comparison (MAIC).

Efficacy outcomes of nivolumab + cabozantinib versus pembrolizumab + axitinib in patients with advanced renal cell carcinoma (aRCC): Matching-adjusted indirect comparison (MAIC).

Abstract Video & Slides Poster

Authors

Bradley McGregor

Bradley Alexander McGregor

Dana-Farber Cancer Institute, Boston, MA

Bradley Alexander McGregor , Daniel M. Geynisman , Mauricio Burotto , Camillo Porta , Cristina Suarez Rodriguez , Maria Teresa Bourlon , Pedro C. Barata , Shuchi Gulati , Brian Stwalley , Viviana Del Tejo , Ella X. Du , Aozhou Wu , Andi Chin , Keith A. Betts , Stephen Huo , Toni K. Choueiri

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Kidney Cancer

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 4578)

DOI

10.1200/JCO.2021.39.15_suppl.4578

Abstract #

4578

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Michael B. Atkins

First Author: Viktor Grünwald

First Author: Pratik Rane

First Author: Joseph Vento